Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Bertoli

Showing results (11-20 of 96) with videos related to

Pageof 10
Sort By:
Leukemia & Lymphoma|June 13, 2018
Outcome of relapsed or refractory acute myeloid leukemia treated with intensive salvage chemotherapy in real life in comparison to intermediate dose cytarabine in phase 3 studiesSarah Bertoli, Suzanne Tavitian, Emilie Berard, et al.
Leukemia Research|May 24, 2015
Hyperferritinemia at diagnosis predicts relapse and overall survival in younger AML patients with intermediate-risk cytogeneticsDelphine Lebon, François Vergez, Sarah Bertoli, et al.
Haematologica|June 29, 2014
Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemiaThomas Prebet, Sarah Bertoli, Jacques Delaunay, et al.
Haematologica|July 15, 2018
Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national surveyPierre Bories, Sébastien Lamy, Célestine Simand, et al.
Cancer Medicine|June 8, 2019
Outcome of patients aged 60-75 years with newly diagnosed secondary acute myeloid leukemia: A single-institution experienceSarah Bertoli, Suzanne Tavitian, Pierre Bories, et al.
Leukemia & Lymphoma|June 22, 2013
Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemiaCaroline Le Jeune, Sarah Bertoli, Mohamed Elhamri, et al.
American Journal of Hematology|September 9, 2014
Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: an analysis from a regional healthcare networkPierre Bories, Sarah Bertoli, Emilie Bérard, et al.
BMC Cancer|September 7, 2019
Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patientsEloïse Berger, Cyrille Delpierre, Fabien Despas, et al.
American Journal of Hematology|October 29, 2015
Impact of obesity in favorable-risk AML patients receiving intensive chemotherapySuzanne Tavitian, Amélia Denis, François Vergez, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 8, 2018
FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid LeukemiaMarielle Perry, Sarah Bertoli, Clément Rocher, et al.
Pageof 10

Showing results (11-20 of 96) with videos related to

Sort By:
Pageof 10
Leukemia & Lymphoma|June 13, 2018
Outcome of relapsed or refractory acute myeloid leukemia treated with intensive salvage chemotherapy in real life in comparison to intermediate dose cytarabine in phase 3 studiesSarah Bertoli, Suzanne Tavitian, Emilie Berard, et al.
Leukemia Research|May 24, 2015
Hyperferritinemia at diagnosis predicts relapse and overall survival in younger AML patients with intermediate-risk cytogeneticsDelphine Lebon, François Vergez, Sarah Bertoli, et al.
Haematologica|June 29, 2014
Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemiaThomas Prebet, Sarah Bertoli, Jacques Delaunay, et al.
Haematologica|July 15, 2018
Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national surveyPierre Bories, Sébastien Lamy, Célestine Simand, et al.
Cancer Medicine|June 8, 2019
Outcome of patients aged 60-75 years with newly diagnosed secondary acute myeloid leukemia: A single-institution experienceSarah Bertoli, Suzanne Tavitian, Pierre Bories, et al.
Leukemia & Lymphoma|June 22, 2013
Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemiaCaroline Le Jeune, Sarah Bertoli, Mohamed Elhamri, et al.
American Journal of Hematology|September 9, 2014
Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: an analysis from a regional healthcare networkPierre Bories, Sarah Bertoli, Emilie Bérard, et al.
BMC Cancer|September 7, 2019
Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patientsEloïse Berger, Cyrille Delpierre, Fabien Despas, et al.
American Journal of Hematology|October 29, 2015
Impact of obesity in favorable-risk AML patients receiving intensive chemotherapySuzanne Tavitian, Amélia Denis, François Vergez, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 8, 2018
FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid LeukemiaMarielle Perry, Sarah Bertoli, Clément Rocher, et al.
Pageof 10